Posted on October 27, 2020 by Sitemaster
We hear that an investigational drug called onvansertib — a so-called polo-like kinase 1 (PLK1) inhibitor — may have benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who are showing early signs of progression on treatment with abiraterone acetate (Zytiga) + prednisone.
… READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, mCRPC, metastatic, onvansertib, Treatment, trial | 1 Comment »
Posted on October 15, 2020 by Sitemaster
A new type of “educational” service has been brought to our attention that uses virtual reality (VR) systems allowing a number of opportunities for men to “talk” to a virtual prostate cancer patient about their own risks for prostate cancer and things like the risks and benefits of PSA testing. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: knowledge, patient, risk, testing, Treatment, virtual | 3 Comments »
Posted on August 23, 2020 by Sitemaster
Two clinical trials have now confirmed the abscopal or bystander effect in prostate cancer. These effects occur when cancer cells that are not directly treated are nonetheless killed. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abscopal, bystander, castration-resistant, effect, metastatic, Treatment | 1 Comment »
Posted on July 23, 2020 by Sitemaster
The idea that most men will recover meaningful erectile and sexual function after treatment for prostate cancer has long been disputed by many in the patient community. We now seem to have some better data supporting the patient perspective. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: erectile, function, QOL, quality of life, sexual, Treatment | 7 Comments »
Posted on September 20, 2019 by Sitemaster
Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy (ADT) among patients initially diagnosed with locally advanced (T3) prostate cancer? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: radiation, stage, surgery, T3, Treatment, trial | 4 Comments »
Posted on March 22, 2019 by Sitemaster
The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. … READ MORE …
Filed under: Uncategorized | Tagged: choice, decision, PreProCare, regret, satisfaction, tool, Treatment, trial | Leave a comment »
Posted on February 7, 2019 by Sitemaster
It has long been appreciated that African-American males have higher risk for diagnosis with prostate cancer, and higher risk for prostate cancer-specific mortality, than those of other ethnic origins living in the US. … READ MORE …
Filed under: Uncategorized | Tagged: African American, aggressiveness, decision-making, disparity, race, Treatment, white | 7 Comments »
Posted on November 27, 2018 by Sitemaster
As we have seen previously (see this link), among men with Gleason 9 or 10 disease, brachy boost therapy (BBT) provided better oncological outcomes compared to either radical prostatectomy (RP) alone or external beam radiation therapy (EBRT) alone. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachy boost, surgery, Treatment, very high-risk | 8 Comments »
Posted on October 22, 2018 by Sitemaster
Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the best” and “the rightest” ways to diagnose, treat, and manage cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: Diagnosis, Prevention, risk, Treatment | 7 Comments »
Posted on October 3, 2018 by Sitemaster
As some of us have long suspected and understood, using data from men treated 20+ years ago as a guide to what would happen if you were treated the same way today is not really a very good idea. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: comparison, outcome, today, Treatment, yesterday | 3 Comments »
Posted on August 20, 2018 by Sitemaster
A recent presentation by Pouliot Frederick, MD, at the annual meeting of the Canadian Urological Association in Halifax, Nova Scotia, provided information on the roles of multiparametric MRI, [18F]choline, and 86Ga-PSMA PET/CT scans in determining the utility and value of salvage radiation therapy (SRT) for patients progressing after first-line surgery. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: radiation, risk, salvage, scan, Treatment | 3 Comments »
Posted on August 2, 2018 by Sitemaster
One of our regular correspondents (who lives in England) was recently told something rather interesting by the Consultant Urologist he sees in the UK. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: change, future, Management, past, progress, Treatment | 4 Comments »
Posted on July 16, 2018 by Sitemaster
As we predicted just a couple of weeks ago, on Friday the US Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: castration-resistant, evidence, nmCRPC, non-metastatic, Treatment | Leave a comment »
Posted on July 11, 2018 by Sitemaster
We recently saw (see this link) that men diagnosed with a Gleason score (GS) of 9 or 10 had lower rates of metastasis and better prostate-cancer survival if … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: 10, aggressive, Gleason, Treatment | 11 Comments »
Posted on June 30, 2018 by Sitemaster
There is a large number of books for patients that deal with a diagnosis and management of prostate cancer. However, there is a relatively small number of books that are really valuable for a large number of men (and their partners) who have to deal with a diagnosis of prostate cancer. Very few books on prostate cancer ever make it into a second edition. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, living, side effects, Treatment | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 